On December 29, 2022, Ms. Trisulee Traisoranakul, Deputy Spokesperson for the Prime Minister’s Office, said that Gen.Prayut Chan-o-cha Prime Minister and Minister of Defense Congratulations on Thailand’s important drug development progress.pharmaceutical organization (Por Por.) Ministry of Public Health Molnupiravir can be developed under the name Monovir in the form of 200 mg capsules and can be produced by yourself, which will replace imports from abroad.
Currently, the drug Molnupiravir It is the main drug used to treat COVID-19. according to the treatment guidelines of Thailand With about 1-200,000 capsules of drug use per day, at this time, the FDA has started producing drugs and is in the process of distributing drugs to public and private hospitals. as medicine for patientsCOVID-19 who are diagnosed to receive molnupiravir, both hospitalized and Or those who have a prescription from a doctor can buy medicines at any of the 8 branches of the District Pharmacy.
“Since the outbreak of COVID-19 Related agencies have conducted research and development in pharmaceuticals, including medicines, vaccines, various screening tools. As for the previous drugs, the FDA was able to successfully produce the drug Favipiravir. And this time we can produce molnupiravir. The Prime Minister sees this as another achievement that emphasizes Thailand’s ability to develop medicine. This is an important foundation for driving Thailand towards the center of medicine and public health,” Ms. Traisulee said.
Ms. Trisulee said that in addition to research and development in the country. Currently, Thailand has cooperation with organizations and foreign countries. Including countries in the ASEAN region about drugs in many dimensions. Most recently, the ASEAN Pharmaceutical Regulatory Framework (APRF) has been driven, which member states are now gradually accrediting. by the operation of the Thai part The Cabinet meeting (Cabinet) on December 27, 2022 saw such a framework and assigned the Minister of Commerce or representative and the Minister of Public Health or representative to jointly certify on behalf of Thailand.
The APRF will be a consistent approach to drug regulation in ASEAN. Ensuring people in the ASEAN region have access to safe, quality and effective medicines. by linking drug regulatory agencies public health and institutions related to close cooperation Lays the basis for the development of the ASEAN Agreement on the Regulation of Drugs (APRF Agreement) as a legal document that establishes the cooperation of ASEAN Member States in pharmaceutical regulation and trade, leading to the implementation of measures. To reduce technical barriers to pharmaceutical product development for the future of the ASEAN pharmaceutical market promote stability Drug self-reliance in the region It ensures immediate access to high-quality, safe, and effective medicines when a disease situation arises.
